medcelerator · clinician one-pager
First FDA-Approved Gene Therapy for Genetic Hearing Loss
OTARMENI (lunsotogene parvec-cwha) — gene therapy for severe genetic hearing loss from biallelic OTOF variants
FDA Approved · United States · September 11, 2026
Condition: Genetic Hearing Loss
Who this is for
This is for children and adults with severe genetic hearing loss from confirmed OTOF gene changes who may be candidates for labelled US OTARMENI gene therapy surgery — when outer hair cells still work and that ear has never had a cochlear implant. It explains the first FDA-approved gene therapy for genetic hearing loss, who fits the US label, Week-24 hearing results from the ongoing CHORD study, surgery and steroid/vaccine prep, procedure risks, and how to talk with an otology / genetics team — without treating the still-recruiting trial as the only route, a company “free product” promise as free hospital care, or a DIY import as a plan. Authorized is not funded.
Next clinical step
The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.
Ways to access this treatment
United States · Prescription
US prescription (FDA-labelled)
https://www.fda.gov/vaccines-blood-biologics/otarmeni
General resources for further research
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/otarmeni-lunsotogene-parvec